Evidence map›Paper›PMID 34939509›Full record

ArticleThe Journal of international medical research2021

Refractory primary extramedullary plasmacytoma in kidney: a case report.

Wenjie Niu, Lili Zhang, Yuhai Wu, Kai Li, Lixia Sun, Hong Ji, Bing Zhang

Open access · goldAbstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenjie NiuDepartment of Urology, 562131Binzhou Medical University Hospital, Binzhou Medical University Hospital, Binzhou City, China.
Lili ZhangDepartment of Endocrinology, 562131Binzhou Medical University Hospital, Binzhou Medical University Hospital, Binzhou City, China.
Yuhai WuDepartment of Urology, 562131Binzhou Medical University Hospital, Binzhou Medical University Hospital, Binzhou City, China.
Kai LiDepartment of Urology, 562131Binzhou Medical University Hospital, Binzhou Medical University Hospital, Binzhou City, China.
Lixia SunDepartment of Pathology, 562131Binzhou Medical University Hospital, Binzhou Medical University Hospital, Binzhou City, China.
Hong JiDepartment of Pathology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao City, China.ORCID https://orcid.org/0000-0003-1996-8989
Bing ZhangDeparment of Urology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao City, China.
Binzhou Medical University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extramedullary plasmacytoma (EMP) is a rare plasma cell neoplasm, with the majority (80-90% of cases) occurring in the upper aerodigestive tract. To our best knowledge, primary EMP from renal tissues is extremely rare. Herein, the diagnosis and treatment of a refractory primary EMP with renal involvement in a 53-year-old male patient is reported. The patient received radical nephrectomy followed by radiotherapy, and showed relapse 3 months after treatment. The cancer cells were sensitive to subsequent chemotherapy, however, the patient died of infection associated with the disease after almost 3.5 years following first presentation.

Indexed as

Multiple MyelomaPlasmacytomaHumansKidneyMaleMiddle AgedNeoplasm Recurrence, LocalNephrectomyExtramedullary plasmacytomakidneyneoplasmnephrectomyrecurrencerefractory

Identifiers

PMID34939509
PMCPMC8829794
OpenAlexW4200205347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.